Company Analysis

BioNexus Gene Lab Corp (BGLC)

Nasdaq: BGLC · Services-Medical Laboratories · Kuala Lumpur, MY · filing with the SEC since 2019
Grade2.8
◀ Past 3.6● Present 2.8▶ Future 2.1
1 est.

Who runs BioNexus Gene Lab Corp

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Tan Lee Su-Leng
Chief Executive Officer. First filing Jul 2026, latest Aug 14, 2026, 0 filings in all.
Officers reporting now
2
of 5 people with a filing in the last fifteen months
Directors reporting now
3
14 people on the record since 2023
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Tan Lee Su-LengChief Executive OfficerJul 2026Aug 14, 2026none
Chong Set FuiChief Financial OfficerJul 2026Aug 14, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Bin Abdul Hamid Muhammad AzruldirectorJul 2026Aug 14, 2026none
Low Jook YuendirectorJul 2026Aug 14, 2026none
Yap Chee KeongdirectorOct 2023Aug 14, 2026none
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Fidelion Diagnostics Pte. Ltd.otherAug 2026Aug 7, 2026none
Earlier names on the record9, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton BGLC · research, not advice